The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.

The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.

First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.

Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.

Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.

Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.